SUMMARY A collaborative study of 75 selected patients with rheumatoid arthritis (RA) employing 6 different methods for the detection of antibodies to type II collagen showed highly significant correlations between all the assays. The radioimmunoassays showed a greater sensitivity than either the passive haemagglutination or immunofluorescent techniques, and when the native collagen molecule was heat-denatured a higher number of patients showed increased antibody levels. In 33 patients the measurement of serum antibody levels to human, bovine, and rat native type II collagen showed a lack of species specificity, indicating that heterologous collagens can be employed in these assays. A retrospective analysis of the clinical, laboratory, and radiological features in the 41 patients with raised antibody levels and the 34 patients with normal antibody levels showed very few differences, but there was a significantly lower incidence of subcutaneous nodules (24 % versus 56 %) in patients with raised antibody levels. This study emphasises the need to standardise assays for the measurement of serum antibody levels to native type II collagen. More extensive studies will be required before the clinical significance of these antibodies can be fully established.
Elevated serum antibody levels to collagen have been detected in patients with rheumatoid arthritis (RA) with different types and species of collagen and a variety of immunological methods.`These differences have led to a marked variation in the reported incidence of these antibodies in patients with RA and have led to difficulties in determining their significance.
The restricted distribution of type II collagen to articular cartilage, the vitreous humour of the eye, and the intervertebral discs makes this collagen of particular relevance in the chronic inflammatory arthritides when compared with the more universal distributions of types I and III collagens.8 Evidence 1 Ag 12I1 anti-human IgG was added in 200 ,ul 0 1 % BSA in PBS -Tween and incubated at room temperature for 4 hours. After a further 3 washes in PBS -Tween the cubes were transferred to new tubes and counted in a gamma counter. The results were calculated after subtracting a BSA control (-2 % of total radioactivity added), and represented as a percentage binding of the highest serum (this represented 14% of total radioactivity added).
Statistics. The upper limits of normal in the radioimmunoassays were calculated as the mean + 3 SD in 15 normal healthy control sera. The correlations between the immunological assays were calculated by the Kendall rank correlation coefficient. Analysis of the differences in the clinical features between the 2 groups of patients was performed by chi-squared analysis. 14 
Results

IMMUNOLOGICAL ASSAYS
The upper limit of normal for each assay is shown in Table 1 . All 10 normal healthy controls and the 4 hospital controls had levels below this limit in all 6 assays. The other 3 patients without apparent RA continued to show elevated antibody levels by one or more assays. The patient with osteoarthritis had a markedly elevated serum IgG antibody level to denatured type II collagen (4-18 mg/I) only. The patient with the undiagnosed arthritis had elevated antibody levels in all 6 assays. There was good agreement between the 5 duplicated sera (data not shown).
The numbers of normal or elevated serum antibody levels in each assav in the 75 patients with RA are shown in Table 1 . The correlations between assays in Table 3 ). The 2 groups were well matched in most features. There was a lower incidence of subcutaneous nodules in the group with elevated antibodylevels(24% v. 56%;X' = 6-50,p = 0-011), and the difference between the groups was significant. There was a higher incidence of patients receiving conventional second-line therapy (44% v. 24 %) and a higher incidence of severe erosive changes on radiology (41 % v. 24 %) in the group withelevated antibody levels, though the differences between the groups were not significant. The details of the other 3 patients with elevated serum antibody levels by one or more assays were also reviewed. The woman with osteoarthritis had no evidence of an erosive arthropathy, though the ESR was elevated at 33 mm/h. The patient with undiagnosed IgG antibody levels to native type II collagen from 42 %6 to 13 % (personal observations). This incidence is still higher than the incidence of 3 % reported with the immunofluorescent technique on rat tracheal cartilage.4 In that study there was an obvious but not exact correlation with the passive haemagglutination technique using native type II collagen extracted from nucleus pulposus.
We have therefore compared 6 assays which could be used for the detection of serum antibodies to type II collagen. The sera were specifically selected for this study, so it is impossible to determine the incidence of these antibodies in RA by each assay. There were good correlations between all assays, though the correlations were better between the 5 assays measuring serum antibodies to the native molecule. The good correlations between the antibodies to cartilage, measured by either radioimmunoassay or immunofluorescence, and antibodies to native type II collagen indicate that these antibodies are capable of binding to cartilage, at least in vitro.
There were differences in the numbers of elevated antibody levels in each assay. Among the immunological methods the radioimmunoassays showed the highest numbers of elevated results, suggesting that they had the greatest sensitivity. However, there was also a difference in incidence even when native type II collagen extracted from different species and tissues (bovine nasal cartilage or human nucleus pulposus) was employed in the same immunological method (passive haemagglutination).
The correlations between serum antibody levels to human native type II collagen and bovine or rat native type II collagen measured in all 3 assays (passive haemagglutination and radioimmunoassays) were very similar (T = 0 76 -0.78). These were the best correlations obtained between all assays, indicating that the use of homologous or heterologous collagens produces only a small difference in the antibody levels. This is not surprising, as the helical or conformational determinant of collagen shows very little interspecies variation."5 16 In all assays more sera gave highertitres to human collagen, suggesting that at least some of the antibody is directed against determinants found only on the human molecule.
The antibody levels to denatured type II collagen were generally higher than to the native molecule together with a higher number of elevated levels in the patients with RA. The upper limit of normal in the control sera was also higher than to the native molecule, though the reason for this is not clear. It is unlikely to be due to fibronectin, as the radioimmunoassay was specifically detecting the binding of IgG antibody. It may indicate that these antibodies are directed against antigenic determinants on the denatured molecule which are hidden in the native molecule, but revealed on heat denaturation. The markedly elevated level in the patient with osteoarthritis suggests that this antibody may be more widespread and less specific than antibody to the native molecule and requires further investigation. This may have similarities to antibodies to DNA, where the antibody to double-stranded DNA is specific for systemic lupus erythematosus, whereas antibody to singlestranded (denatured) DNA is less specific."7
The significance of these antibodies is uncertain. The restricted distribution of type II collagen, which is mainly found in articular cartilage, might suggest that measurement of serum antibody levels to this antigen may give an indication of the severity of joint destruction (loss of articular cartilage It is not known whether these antibodies are merely the result of damage to articular cartilage and thus an index in some patients of the extent of articular damage, or whether they also play a pathogenic role and thus lead to further damage to the articular cartilage.
Evidence for a pathogenic role of these antibodies is supported by 2 studies in native type II collageninduced arthritis in the rat. This arthritis can be induced in naive rats by the passive transfer of serum alone containing antibodies to native type II collagen.'8 The depletion of serum complement in rats with cobra-venom factor delaysthe induction of native type II collagen-induced arthritis until the serum complement levels have returned towards normal levels. '9 These 2 studies suggest a direct role for these antibodies in the induction of this arthritis in the rat, but their role in patients with RA remains uncertain.
This study demonstrates the good correlations between the different immunological methods available for measuring serum antibody levels to native type II collagen, though there were differences in the sensitivities of the various assays. This does not account for the wide variation in the reported incidence ofthese antibodies in RA. Our radioimmunoassays were modified to allow for nonspecific binding of immunoglobulins and this reduced the incidence of antibodies to native type II collagen to a considerable extent. We now feel that the major factor in reporting a high incidence of these antibodies in RA has been the detection of nonspecifically bound immunoglobulins by highly sensitive radioimmunoassays. All sensitive immunological assays should therefore allow for nonspecific binding of immunoglobulins in their methodology.
However, even when nonspecific binding of immunoglobulins is allowed for, there will still be minor variations in the incidence of these antibodies to RA. These will be due to a combination of factors in the methodology and patient selection. The former includes the sensitivity of the immunological method, as well as the species, and the native or denatured state of the collagen. Patient selection could also account for variation as the true incidence ofthese antibodies in certain racial or ethnic groups with RA, and the effects of therapy on antibody levels are not yet known. Standardisation of these methods, as has already been established for serum antiglobulins, will be necessary before the true incidence of these antibodies can be determined in patients with rheumatoid arthritis. Further long-term studies on patients are required before the significance of these antibodies can be determined. 
